Adherence to treatment and antipsychotic levels in saliva in patients with a first psychotic episode by Uribe Viloria, Nieves De
, 
     ADHERENCE TO TREATMENT AND 
ANTIPSYCHOTIC LEVELS IN SALIVA IN 
PATIENTS WITH A FIRST PSYCHOTIC 
EPISODE 




MÁSTER UNIVERSITARIO EN INTRODUCCIÓN A 
LA INVESTIGACIÓN EN SALUD MENTAL 
 
UNIVERSITY OF CANTABRIA 
 








STUDENT: Nieves De Uribe Viloria  
TUTOR: Ana González-Pinto Arrillaga 
RESEARCH TEAM: G10 CIBERSAM, Hospital Universitario de Alava 




I would like to thank the G10 CIBERSAM research team, for donating the data and for their 
advice in the writing and editing of the text, and all the centres participating in the project 
“Clinical applicability of a predictive model of relapse in first episodes of schizophrenia”, based 
on the previous project “Clinical and neurobiological determinants of second psychotic episodes, 
longitudinal study of first psychotic episodes” (“Determinantes clínicos y neurobiológicos de 








Introduction. Adherence plays a key role in promptly achieving and maintaining remission in 
Schizophrenia. Thus, monitoring adherence is of utmost importance to optimize treatments, and 
evidence suggests that this can be done by measuring salivary levels of antipsychotics, which 
could have several advantages over the traditional plasma level monitoring.  
Aims. We aim to study the relationship between adherence, salivary levels of antipsychotics and 
clinical outcomes after a first episode psychosis.   
Material and methods. This multicentre study includes 223 patients diagnosed of first episode 
of psychosis (FEP) in remission in the moment of recruitment. We compared salivary levels of 
antipsychotics, EEAG and PANSS scores in the adherent versus the non-adherent group. 
Results. Adherence increased from baseline (49%) to three (52%) and six months (60%). All 
antipsychotics could be measured in saliva, and there was a positive correlation between saliva 
and blood levels of Aripiprazole. Adherent patients had a significative decrease in score in 
PANSS Negative scale (F =4.779, p= 0.010) and a tendency to this in PANSS Global scale. 
PANSS Positive scale and EEAG did not show different outcomes between the two adherence 
groups.  
Conclusions. There is a positive correlation between plasma and salivary levels for Aripiprazole, 
and such levels are related with dose in adherent patients. Levels of non- adherence are high, 
almost 50% in first psychotic episode patients., and are associated with higher negative symptoms 
in follow-up. Further studies should be made to better establish the relationship between salivary 
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Psychiatric disorders are a public health challenge, being attributed 14% of the global burden of 
disease (Semahegn et al., 2018). They affect approximately 450 million people and are the main 
cause of the years lived with long-term disabilities and dependency (Nicolino, Vedana, Miasso, 
Cardoso, & Galera, 2011; Semahegn et al., 2018). Depressive disorders (350 million), bipolar 
disorders (60 million) and schizophrenia (21 million) are the most common psychiatric 
conditions (World Health Organization, 2016). Schizophrenia is one of the most disabling, 
affecting 1% of the population, compromising various areas of patient’s lives and representing an 
important burden in social and financial terms, not only for patients but also for caregivers and 
society (Nicolino et al., 2011).  
Prognostic factors in schizophrenia include adequate treatment and adherence, duration of 
untreated psychosis (DUP), number of relapses and comorbid substance use. Early intervention 
in these factors is key to the course of illness, making first episode psychosis a question of utmost 
interest in clinic and research. Symptomatic remission, which criteria were defined by the 
Remission in Schizophrenia Working Group (Andreasen et al., 2005) is of prognostic value for 
social functioning and quality of life in schizophrenia. Thus, promptly achieving and maintaining 
remission is a key factor in reducing the long-term burden of the illness.  
Patients with first episode psychosis usually respond well to treatment, but relapse is frequent 
during the first years, and may be associated with clinical deterioration (Robinson et al., 1999). 
Literature agrees that in the first year, relapse rates are low, although they rise substantially after 
two and five-year follow-up. Discontinuation of medication is the most important variable 
associated with relapse (Koutsouleris et al., 2016). 
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Achieving therapeutic levels is essential in order to balance effective management of the 
symptoms with minimal adverse effects, and is determined mainly different factors: dosage, 
metabolic differences among individuals and mostly, treatment compliance.  
According to the WHO, adherence means “a case in which a person’s behaviour in taking 
medication corresponds with agreed recommendations from health personnel”. Whereas 
antipsychotic treatment has proven to be effective, maintaining adherence is difficult (Leclerc, 
Noto, Bressan, & Brietzke, 2015). Nonadherence rates among psychiatric patients are high 
(Haddad, Brain, & Scott, 2014), approximating 50% a year after a first episode of psychosis 
(Coldham E. L., Addington J., & Addington D., 2002). Lack of treatment compliance is 
associated with worse prognosis and greater probability of relapse and rehospitalization (Crespo-
Facorro et al., 2011; Nicolino et al., 2011; Robinson et al., 1999).  
Adherence is a complex behaviour  and non-adherence to medication is multifactorial (Hartung 
et al., 2017). Some studies highlight the necessity of differentiating between intentionally non-
compliant patients and those who cannot properly comply due to difficulties understanding and 
remembering the prescription, as its causes and kind of intervention needed may differ for each 
group.  
Factors associated with intentional non-compliance included younger age, substance abuse, 
forensic history, lower functioning level, positive symptoms, longer duration of untreated 
psychosis, lack of insight, self-stigmatization, side effects, dissatisfaction with information 
received, and negative beliefs and attitudes towards the illness and medication (Barbeito et al., 
2014; Feldhaus et al., 2018; García et al., 2016; Leclerc et al., 2015; Nicolino et al., 2011), the 
latter being the most significant ones in predicting non-adherence (Hickling, Kouvaras, Nterian, 
& Perez-Iglesias, 2018). This agrees with the Health Belief Model, which poses that patients are 




There is evidence that compliance of some psychiatric treatments can be monitored through 
salivary measures. For instance, salivary and blood correlations have been observed for 
chlorpromazine, clozapine, diazepam, lithium and valproate (Jain et al., 2011; May, Van Putten, 
Jenden, & Cho, 1978; Murru et al., 2017; Yamazumi & Miura, 1981). However, salivary 
medication and biomarker measurements are often overlooked in medicine; issues like oral 
contamination, restriction to selective drugs in unionized form and pH influenced-fluctuations 
have contributed to this. On the other hand, the use of saliva in measuring drug concentrations 
has several advantages: easy and faster sampling, better acceptance from the patients as it poses 
no risks or pain, more convenient for health professionals… all of which allows for more 
frequent monitoring; besides, salivary measurements may be better for highly protein-bound 
drugs, as they represent only the unbound fraction, contrary to plasma levels that measure both 








HYPOTHESIS AND OBJECTIVES  
HYPOTHESIS:  
Antipsychotics can be measured in saliva.  
Adherence to antipsychotic medication can partially predict the outcome after a first episode of 
psychosis. 
OBJECTIVES:  
Main objective:  
To determine if antipsychotics can be measured in saliva  
Secondary objectives:  
1. To describe the sociodemographic aspects of patients with first episode psychosis  
2. To study the relationship between salivary and plasma levels of antipsychotics  
3. To study the relationship between adherence and salivary levels of antipsychotics  
4. To establish a relationship between salivary levels of antipsychotics and psychotic 
symptoms  




MATERIAL AND METHODS  
Data for this study was taken from the multicentric longitudinal cohort study “Clinical 
applicability of a predictive model of relapse in first episodes of schizophrenia – Estudio de 
aplicabilidad clínica de un modelo predictivo de recaídas en primeros episodios de esquizofrenia”, 
in which Dr. Gonzalez-Pinto is the coordinator of the adherence package. The database 
consisted in 223 patients (148 men and 64 women, age range 19-40 years), recruited from 
different hospitals participating in the multicentre study,  with diagnosis of first episode of 
psychosis (FEP) in remission in the moment of recruitment, divided in adherent and non-
adherent to medication.  
Inclusion criteria in the original study included:  
1. Age between 16 and 40 
2. Meet diagnostic criteria for first episode of psychosis  
3. Meet Standardized Remission Criteria in schizophrenia (Andreasen et al., 2005) 
4. Not having suffered from a relapse since debut of illness 
5. Speak Spanish fluently 
6. Having signed the Informed Consent.  
Exclusion criteria for the original study were: 
1. Traumatic brain injury accompanied by loss of consciousness 
2. Intellectual disability, understood not only as CI under 70, but also by developmental 
difficulties 
3. Somatic pathology that may have mental repercussions.   
Data available included socio-demographic, clinical and biological variables. Socio-demographic 
variables included age, gender, education, socioeconomic status. Clinical variables included 
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psychotic symptoms, functionality and relapses. Socio-demographic and clinical data were 
gathered in semi-structured interviews conducted by mental health professionals, in which the 
following questionnaires were administered.  
Adherence was measured using the Morisky-Green test, an autoaplicated questionnaire validated 
for the assessment of compliance to treatment (Culig & Leppée, 2014; Morisky, Green, & Levine, 
1986). Spanish version was validated by Val Jimenez et al. (Val Jiménez, et al.,, , 1992). Measures 
were gathered at baseline and three and six months after recruitment. Global adherence was 
evaluated considering the three measures, being adherent when obtaining positive adherence in 
two or more out of three visits. 
Functionality was assessed with the Spanish version of the GAF – Global Assessment of 
Functionality scale,  the EEAG – Escala de Evaluación de la Actividad Global (Jones, 
Thornicroft, Coffey, & Dunn, 1995). Assessment was made at baseline and at three and six 
month follow-up. 
Psychotic symptoms were assessed at baseline and three and six month follow-up, using the 
PANSS – Positive And Negative Syndrome Scale (Kay, Fiszbein, & Opler, 1987), Spanish 
version by Peralta and Cuesta (Peralta & Cuesta, 1994).  
Biological parameters consisted in saliva samples collected in order to determine saliva levels of 
the following antipsychotics: risperidone, paliperidone, olanzapine, quetiapine and aripiprazole. 
Sampling was conducted at baseline, and three and six months after remission. Samples were 
collected without stimulation, using tubes specially adapted for saliva (Salivette o SARSTEDT®, 
nº REF51.1534.001). The tubes were kept at – 20ºC until analysis. Saliva was extracted by 
centrifugation at 2500 g for 10 minutes and analysed with liquid chromatography-tandem mass 
spectrometry, only in those cases in which three samples for the same patient were collected. 
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Data analysis was carried with the programme SPSS Statistics for Windows, version 23, and the 
level of significant was set at p<0.05. For the sociodemographic variables, comparisons between 
the adherence groups were made using bivariate analyses. T-Student tests for independent 
samples were used for continuous variables and contingency tables for categorical variables.  
The association between salivary levels and the dose of antipsychotics was evaluated with 
Pearson correlations. The relation between adherence and the salivary levels of antipsychotics as 
well as the association between the salivary levels and the clinical symptoms were analysed 
following a two-step procedure:  
1. First, we performed a multiple linear regression including in the models all the potential 
confounders. Only those significant variables or those that produced a significant change 
in the coefficient of the independent variable were included in the final model. Finally, 
the interaction terms were evaluated.  
2. Once the final model was performed, we included the dose of the antipsychotic as 
confounding variable in order to evaluate its mediation effect. 
ETHICAL ASPECTS:  
The original project from which this study feeds was granted approval by the Ethical Committees 













Gender Male 97 (67.8%) 52 (71.2%) 45 (64.3%) X2= 0.790,  
p=0.374 Female 46 (32.2%) 21 (28.8%) 25 (35.7%) 
Age  26.40 (6.24) 26.51 (6.16) 26.29 (6.36) t= 0.211,  
p= 0.833 
SE level Low 35 (26.7%) 18 (26.1%) 17 (27.4%) X2= 0.866,  
p= 0.649 Medium 58 (44.3%) 33 (47.8%) 25 (40.3%) 
High 38 (29.0%) 18 (26.1%) 20 (32.3%) 
Education 
level 
No studies 12 (8.5%) 7 (9.6%) 5 (7.2%) X2= 3.502,  
p= 0.320 Basic 36 (25.4%) 22 (30.1%) 14 (20.3%) 
Secondary 61 (43.0%) 31 (42.5%) 30 (43.5%) 
University 33 (23.2%) 13 (17.8%) 20 (29%) 
Cannabis use  82 (57.3%) 46 (63%) 36 (51.4%) X2= 1.961,  
p= 0.161 
Drug ARI 50 (37.9%) 26 (38.8%) 24 (36.9%) X2= 0.050,  
p= 0.824 
CLO 10 (7.6%) 4 (6.0%) 6 (9.2%) X2= 0.501, 
p= 0.479 
OLA 28 (21.2%) 13 (19.4%) 15 (23.1%) X2= 0.266,  
p= 0.606 
PAL 33 (25.2%) 19 (28.4%) 14 (21.9%) X2= 0.730,  
p= 0.393 
RIS 22 (16.8%) 11 (16.4%) 11 (17.2%) X2= 0.014,  
p= 0.906 
     Table 1 
As showed in Table 1, no significative differences were observed between the adherence groups.  
Adherence increased from baseline (49% = 70/143) to three months (52% = 59/114), and 





All antipsychotics could be measured in saliva, with levels varying as shown in Table 2:  
 Visits 
 Baseline 3 months 6 months 
Aripiprazole 11.89 (69.72) 2.92 (11.49) 2.41 (5.68) 
Clozapine 21.44 (46.08) 37.80 (48.93) 14.63 (28.66) 
Olanzapine 27.67 (89.31) 9.94 (17.09) 7.11 (8.91) 
Risperidone 3.69 (7.78) 0.64 (0.72) 0.39 (0.48) 
Paliperidone 11.91 (11.78) 10.61 (13.00) 8.98 (11.04) 
Table 2 
Relationship between salivary and plasma levels of antipsychotics  
We found a positive correlation between saliva and blood levels of Aripiprazole at three (r= 
0.580, p= 0.001) and six months (r= 0.506, p= 0.027). Although we did not reach significance for 
the rest of the data analysed, we see a tendency to positive association.  
Relationship between dose and salivary levels of antipsychotics: 
No relationship between dose and saliva levels was found in the non-adherent group for any of 
the medications studied.  
In the adherent group, we found a significative relationship at baseline between dose and saliva 
levels of Aripiprazole (r= 0.743, p<0.001). We did not find significative relationship between 
dose and saliva levels of Olanzapine, Clozapine, Risperidone and Paliperidone. 
Relationship between global adherence and clinical outcome: 
Global adherence was aby being achieved when being adherent in at least two out of three visits 
(baseline, 3 months and 6 months). Patients who were globally adherent obtained better 
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outcomes in the PANSS Negative scale, with a significant decrease in the score (F =4.779, p= 
0.010) when compared with the non-adherent group (Table 3, Figure 1); a tendency to this was 
also observed in the PANSS Global scale (Table 4, Figure 2), though results did not reach 
statistical significance (F= 3.326, p= 0.072). PANSS Positive scale and EEAG did not show 
different outcomes in the adherent group in comparison to the non-adherent group, as in shown 
in Table 5.  
PANSS Negative Adherent Non-adherent 
Baseline 15.00 (0.79) 13.29 (0.85) 
3 months 13.45 (0.71) 13.33 (0.77) 








PANSS Global Adherent Non-adherent 
Baseline 49.00 (1.93) 48.02 (2.09) 
3 months 45.39 (1.84) 47.45 (1.99) 




PANSS Positive Adherent Non adherent 
Baseline 9.30 (3.12) 9.31 (2.77) 
3 months 8.64 (2.48) 9.31 (3.01) 
6 months 8.65 (3.12) 9.17 (3.04) 
EEAG Adherent Non adherent 
Baseline 68.02 (13.92) 68.40 (13.10) 
3 months 72.35 (13.41) 70.58 (11.65) 






Salivary antipsychotic levels and symptoms 
At baseline, higher levels of Aripiprazole were associated with higher scores in the PANSS 
Global scale (b= 0.052, p= 0.023); the results did not vary when introducing dose as a 
confounding variable. At three months, higher Aripiprazole levels where associated with higher 
scores in the PANSS Positive scale (b= 0.012, p= 0.008); once again, results did not vary when 
introducing dose as a confounding variable. 
At baseline, higher Clozapine levels, were associated with lower scores in the PANSS Negative 
scale (b= -0.081, p= 0.024) and in the PANSS Global scale (b= -0.220, p= 0.011). We obtained 
similar results at three months, both in the PANSS Negative scale (b= -0.109, p= 0.014) and in 
the PANSS Global scale (b= -0.300, p<0.001), and at six months in the PANSS Negative scale 
(b= -0.175, p= 0.021). We found no variation in results in none of the visits (baseline, and three 
and six months) when including dose as a confounding variable.  
Regarding the EEAG scale, although there was no relation neither at baseline nor at 3 months, at 
6 months there was a significant mediation of the Clozapine dose in the relationship between the 
salivary levels of Clozapine and the scores of the EEAG scale; at first  the relation between 
salivary levels and the EEAG scale was not significant (b= 0.134, p= 0.465), but when including 
dose as covariable, both the dose and the relation between salivary levels and EEAG became 





All antipsychotic and their metabolites could be measured in saliva. This is a relevant finding, as 
saliva levels can be a tool to check compliance, in order to take the correct decisions in clinical 
settings. In fact it is not unusual to increase the dose of antipsychotics in order to improve 
symptoms, when the problem is lack of adherence and it would probably be a better approach to 
give information about efficacy and prognosis. In addition, we found a positive correlation 
between plasma and salivary levels for Aripiprazole. This finding poses special importance, as 
there are no previous studies about the relationship between aripiprazole in plasma and saliva. 
Previous studies found correlations between plasma and salivary levels for Chlorpromazine, 
Clozapine, Diazepam, Lithium and Valproate (Jain et al., 2011; May et al., 1978; Murru et al., 
2017; Yamazumi & Miura, 1981). Our findings about  Risperidone and Olanzapine, go in line 
with these results. The lack of correlation between plasma and salivary levels in our study for 
Clozapine and Paliperidone could be explained by the shortage of subjects with available data in 
this pharmacologic group.  This differences in results between pharmacologic groups could also 
be explained by the fact that high protein-binding antipsychotics, such as Aripiprazole, could be 
easier to determine in saliva than others. In fact, it interesting to point out that we found a 
relationship between aripiprazole dose and saliva levels.  
Saliva offers some advantages over plasma, its sampling being simple, stress-free, non-invasive 
and more convenient than blood testing for health care provider and patient, allowing multiple 
collections in a day at any place; it is also able to measure the “unbound” biologically active or 
free hormone levels. Disadvantages to consider would be the possible interference with 
substances such as food and beverages and contamination of the oral mucosa, so restrictions 




Levels of adherence in our patients are similar to those found in other studies, being adherent 
about half of the sample studied. Adherence increased slightly during the first year of follow up. 
Other investigators found high levels of non-adherence to medication (Haddad et al., 2014), 
approximating 50% a year after a first episode of psychosis (Coldham E. L. et al., 2002). Lack of 
treatment compliance is associated with worse prognosis and greater probability of relapse and 
rehospitalization (Crespo-Facorro et al., 2011; Nicolino et al., 2011; Robinson et al., 1999).  
Our study did  show better results in negative symptoms in adherent patients than in non-
adherent patients, which relevance resides in the fact that negative symptoms area common, 
enduring and debilitating component of the psychopathology of schizophrenia (Stahl & Buckley, 
2007). They are associated with higher levels of impairment and poorer outcomes (Vella & Pai, 
2015), having greater impact on functioning than positive symptoms (Rabinowitz et al., 2012) and 
are also more challenging to evaluate objectively (Stahl & Buckley, 2007) to treat, being the 
effects of current psychopharmacological treatments at best modest (Buckley & Stahl, 2007). 
These findings could serve as a start point for more studies about the optimization of 
pharmacological strategies to tackle negative symptoms and their effects in long-term follow-up. 
Lack of association with EEAG could be explained by the high functionality levels of our 
patients, and by shortness of the follow-up (most of the patients in the moment of the analysis 
hadn’t reached one year since recruitment), which could have not been enough time for deficits 
to appear. Also, lack of association between adherence and positive symptoms is probably due to 
low positive symptoms in this sample. Both our results and current literature support the 
importance of adherence to treatment as a prognostic factor in schizophrenia. A metanalysis by 
García et al. (García et al., 2016) highlights the prognostic relevance of early interventions 
focused on adherence enhancement. Novick et al (Novick et al., 2010) links non-adherence in 
schizophrenia to an increased risk of relapse, hospitalization and suicide attempts. Myers et. al 
(Myers, Bhatty, Broussard, & Compton, 2017) link non-adherence to greater positive symptom 
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severity and likelihood of continuing drug-use. Regarding the strategies for improving adherence, 
psychoeducation family interventions and motivational therapy have been associated with an 
improve in compliance; and long-acting injectable antipsychotics are among pharmacological 
strategies gaining popularity (Greene et al., 2018; Hartung et al., 2017). Nonetheless medication 
adherence continues to be one of the main challenges in assessment of first episode psychosis, an 
idea that is consistent with the results of our study, in which only 49% of the patients were 
adherent at baseline, a proportion that only increased slightly at three months (52%), and six 
months (60%), meaning that an important fraction of patients remain undertreated even after 
months of psychiatric follow-up.  
The positive correlation between higher levels of antipsychotics and higher results in PANSS 
scale could be explained by the fact that prescription is guided by symptoms, so more 
symptomatic patients would receive higher doses of medication, thus accounting for the higher 
levels.   
LIMITATIONS: 
One limitation shared with most longitudinal studies is the loss of subjects, due to the frequency 
and long-term duration of the project.  
Other  limitation lies in inter-observer differences in clinical assessment, although we expect 
these differences to be minor due to the specific training of the mental health professionals and 
the use of validated tests.  
We also need to consider that, as the original project is yet to finish, data available is limited and 
the preliminary results than can be obtained may not be of statistical or clinical significance. For 
instance, data about Aripiprazole and Paliperidone include both oral and intramuscular 
treatments. The sample was too small to do separate analyses, although we cannot exclude 
significant results with Paliperidone with larger samples of oral or intramuscular treatments. 
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Considering the use of biological samples, known for their variability, and the shortage of data 
available, a non-parametric approach could have been more adequate, in spite of this we choose 
to conduct parametric analysis in order to be less restrictive with the analysis.  
Lastly, shortage of data hindered the establishment of a relationship between variables, although 






- Antipsychotics can be measured in saliva 
- There is a positive correlation between plasma and salivary levels for Aripiprazole.  
- Levels of aripiprazole in saliva are related with the dose in adherent patients.  
- Levels of non-adherence are high, almost 50% in first psychotic episode patients.  
- Adherence is associated with lower negative symptoms in follow-up.  
- Further studies should be made to better establish the relationship between salivary and 
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